Valuation Cumberland Pharmaceuticals Inc.

Stocks

Real-time Estimate Cboe BZX 00:02:26 04/11/2026 +04			5-day change	1st Jan Change
4.340 ^USD	+2.84%		-13.13%	+8.04%

10-27	Cumberland Pharmaceuticals Inc. - Special Call
10-27	Cumberland Pharmaceuticals Inc. Announces Plans To Submit New Drug Application To FDA For Ifetroban As Potential Treatment For Cardiomyopathy Associated With Duchenne Muscular Dystrophy	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2020	2021	2022	2023	2024	2025
Market Cap ¹	44.3	68.9	32.54	26.7	33.28	59.53
Change	-	55.54%	-52.77%	-17.94%	24.62%	78.87%
Enterprise Value (EV) ¹	36.62	57.92	33.75	26.81	35.89	58.26
Change	-	58.17%	-41.74%	-20.55%	33.85%	62.34%
P/E	-13.4x	-19.8x	-5.88x	-4.07x	-5.14x	-20.8x
PBR	0.94x	1.61x	0.89x	0.85x	1.45x	2.39x
PEG	-	-2.73x	-0.1x	-0.3x	-1.08x	0.4x
Capitalization / Revenue	1.18x	1.91x	0.77x	0.68x	0.88x	1.34x
EV / Revenue	0.98x	1.61x	0.8x	0.68x	0.95x	1.31x
EV / EBITDA	-22.4x	-18.9x	-89.6x	-21x	-23.5x	43.1x
EV / EBIT	-5.74x	-7.54x	-5.92x	-4.32x	-5.58x	-20.9x
EV / FCF	-19.5x	160x	14x	2.87x	-45x	9.05x
FCF Yield	-5.12%	0.62%	7.12%	34.8%	-2.22%	11.1%
Dividend per Share ²	-	-	-	-	-	-
Rate of return	-	-	-	-	-	-
EPS ²	-0.2202	-0.2362	-0.3825	-0.44	-0.4609	-0.1909
Distribution rate	-	-	-	-	-	-
Net sales ¹	37.44	35.99	42.01	39.55	37.87	44.52
EBITDA ¹	-1.633	-3.071	-0.3768	-1.275	-1.53	1.353
EBIT ¹	-6.382	-7.677	-5.705	-6.211	-6.432	-2.792
Net income ¹	-3.339	-3.508	-5.57	-6.279	-6.48	-2.836
Net Debt ¹	-7.677	-10.98	1.201	0.1069	2.608	-1.264
Reference price ²	2.950	4.670	2.250	1.792	2.370	3.980
Nbr of stocks (in thousands)	15,017	14,755	14,464	14,905	14,042	14,957
Announcement Date	12/03/21	11/03/22	13/03/23	13/03/24	07/03/25	09/03/26

¹USD in Million²USD

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
CUMBERLAND PHARMACEUTICALS INC.	-	-	-	-	63.23M
ELI LILLY AND COMPANY	41.24x	13.98x	31x	0.48%	1,257B
JOHNSON & JOHNSON	39.6x	6.65x	18.71x	1.97%	651B
ABBVIE INC.	36.2x	8.44x	17.42x	2.4%	510B
ROCHE HOLDING AG	21.41x	5.2x	12.95x	2.52%	388B
MERCK & CO., INC.	98.19x	6.02x	25.62x	2.29%	366B
NOVARTIS AG	22.92x	5.89x	14.21x	2.72%	303B
ASTRAZENECA PLC	24.43x	4.89x	13.76x	1.79%	288B
AMGEN INC.	29.52x	7.52x	13.46x	2.17%	252B
GILEAD SCIENCES, INC.	-40.78x	7.43x	46.67x	1.94%	211B
Average	30.30x	7.34x	21.53x	2.03%	422.67B
Weighted average by Cap.	36.23x	8.78x	22.70x	1.71%